7623-03-2

Basic information

• Product Name: 4-(2-chloroethyl)benzoyl chloride
• Synonyms: 4-(2-chloroethyl)benzoyl chloride
• CAS NO: 7623-03-2
• Molecular Weight: 203.068
• Mol File: 7623-03-2.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 4-(2-chloroethyl)benzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-chloroethyl)benzoyl chloride(7623-03-2)
• EPA Substance Registry System: 4-(2-chloroethyl)benzoyl chloride(7623-03-2)

Safety Data

• Hazardous Substances Data: 7623-03-2(Hazardous Substances Data)

Upstream product

• 20849-78-9 p-(beta-chloroethyl)benzoic acid 

Downstream Products

• 1622204-10-7 5-((2-(4-(2-(4-ethylpiperazin-1-yl)ethyl)benzamide)pyridin-4-yl)oxy)-6-methoxy-N-methyl-1H-indole-1-carboxamide 

Relevant articles and documents

Pairwise Proximity-Differentiated Visualization of Single-Cell DNA Epigenetic Marks

Spatial positioning and proximity of relevant biomolecules such as DNA epigenetic marks are fundamental to a deeper understanding of life. However, it remains poorly explored and technically challenging. Here we report the pairwise proximity-differentiate

MONOCYCLIC PYRIDINE DERIVATIVE

The present invention provides a novel compound having FGFR inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. Specifically, the present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein n represents 0 to 2; A represents an arylene group or a heteroarylene group; G represents a single bond, an oxygen atom or —CH2—; E represents a nitrogen-containing non-aromatic heterocycle; R1 represents an alkoxy group or the like; R2 represents a hydrogen atom or the like; and R3 represents a hydrogen atom, an alkyl group, an alkoxy group or the like, with the proviso that when E represents an azetidine ring and R2 or R3 is present on a nitrogen atom on the azetidine ring, the R2 or R3 does not represent a hydrogen atom.

HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the